Compare Roblox Corp (RBLX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Summit Therapeutics Inc — how do they compare? Roblox Corp trades at $49.6 (market cap $37.59B), while Summit Therapeutics Inc trades at $14.75 (market cap $11.34B). The key difference: Roblox Corp is far larger — about 3.3× Summit Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| RBLX | SMMT | |
|---|---|---|
Market Cap | $37.59B | $11.34B |
Sector | Media | Health |
52-Week High | $141.56 | $29.32 |
52-Week Low | $41.30 | $13.05 |
Enterprise Value | $36.18B | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox trades at $52.50, up 1.59% with neutral technical signals. The company shows strong revenue growth reaching $4.89B in 2025 but continues to report significant losses with a -20.69% net margin. Analyst consensus is bullish with a $59.62 price target, though multiple class action lawsuits filed in July 2026 create near-term uncertainty. Operating cash flow improved to $1.8B, supporting ongoing platform investments.
Roblox presents a growth investment case with expanding user engagement and AI innovation, but profitability challenges and legal risks require careful monitoring. The stock offers 13.6% upside to consensus target, though high P/S ratio of 7.03 and negative ROE of -295.16% highlight valuation concerns amid persistent losses.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
